DXCM (DexCom) Construction In Progress : $349 Mil (As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is DexCom Construction In Progress?

DexCom's quarterly construction in progress increased from Mar. 2024 ($275 Mil) to Jun. 2024 ($285 Mil) and increased from Jun. 2024 ($285 Mil) to Sep. 2024 ($349 Mil).

DexCom's annual construction in progress increased from Dec. 2021 ($361 Mil) to Dec. 2022 ($543 Mil) but then declined from Dec. 2022 ($543 Mil) to Dec. 2023 ($328 Mil).

DexCom Construction In Progress Historical Data

The historical data trend for DexCom's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Construction In Progress Chart

DexCom Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

132.60

219.00

360.70

542.60

328.10

DexCom Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Construction In Progress	Get a 7-Day Free Trial															343.10	328.10	274.90	284.70	349.20

DexCom Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

DexCom Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

DXCM:Mexico 0A4M:UK DC4:Germany DC4:Germany DC4:Germany DC4:Germany D1EX34:Brazil DXCM:Austria

Address

6340 Sequence Drive, San Diego, CA, USA, 92121

Website

https://www.dexcom.com

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Executives

Sadie Stern	officer: Chief Human Resources Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Jereme M Sylvain	officer: SVP, Finance & CAO	6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Bridgette P Heller	director	TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Jacob Steven Leach	officer: SVP, Research & Development	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Micheal Jon Brown	officer: EVP, Chief Legal Officer	6340 SEQUENCE DR, SAN DIEGO CA 92121
Mark G Foletta	director	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Matthew Vincent Dolan	officer: *	6340 SEQUENCE DR, SAN DIEGO CA 92121
Kevin R Sayer	director
Teri L Lawver	officer: EVP Chief Commercial Officer	C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman	director
Nicholas Augustinos	director	754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Steven Robert Pacelli	officer: Vice President Legal Affairs	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan	officer: EVP Chief Technology Officer	C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan	officer: EVP Operations	1023 CHERRY ROAD, MEMPHIS TN 38117
Rimma Driscoll	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054